lost $700 million. No HGSI drug had reached the market, although the most advanced had entered clinical trials. By March 2004 HGSI stock was trading at $11, down from more than $100 in 2000.
Venter headed the Institute for Genomic Research (TIGR), the nonprofit research branch of HGSI, while Haseltine headed the for-profit side of the company. The plan was for TIGR to begin sequencing the human genome and sell its data to HGSI
drugs to fight anthrax and other bioterrorist threats. Such drugs did not require human trials and could be stockpiled by the government prior to approval
publishing his data in academic journals. Just months after establishing the partnership, Haseltine set up his own DNA-sequencing program at HGSI. His relationship with Venter formally ended in 1997
A distinguished scientist, William A. Haseltine founded Human Genome Sciences (HGSI) to sequence the DNA in human genes, boasting that his activities would lead to the immediate development of an array of new drugs for treating diseases